GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PuriBlood Medical Co Ltd (ROCO:6847) » Definitions » EBIT

PuriBlood Medical Co (ROCO:6847) EBIT : NT$-45.5 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is PuriBlood Medical Co EBIT?

PuriBlood Medical Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$-11.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-45.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PuriBlood Medical Co's annualized ROC % for the quarter that ended in Jun. 2024 was -22.50%. PuriBlood Medical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -36.80%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PuriBlood Medical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -3.31%.


PuriBlood Medical Co EBIT Historical Data

The historical data trend for PuriBlood Medical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuriBlood Medical Co EBIT Chart

PuriBlood Medical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -19.82 -1.70 -37.29 18.25 -53.07

PuriBlood Medical Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 5.43 12.82 -19.45 -33.62 -11.87

Competitive Comparison of PuriBlood Medical Co's EBIT

For the Diagnostics & Research subindustry, PuriBlood Medical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuriBlood Medical Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PuriBlood Medical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PuriBlood Medical Co's EV-to-EBIT falls into.


';

PuriBlood Medical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-45.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PuriBlood Medical Co  (ROCO:6847) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PuriBlood Medical Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-26.896 * ( 1 - -1.34% )/( (119.408 + 122.867)/ 2 )
=-27.2564064/121.1375
=-22.50 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=265.512 - 31.342 - ( 117.482 - max(0, 39.893 - 154.655+117.482))
=119.408

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

PuriBlood Medical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-23.74/( ( (54.876 + max(5.163, 0)) + (52.492 + max(16.498, 0)) )/ 2 )
=-23.74/( ( 60.039 + 68.99 )/ 2 )
=-23.74/64.5145
=-36.80 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8.403 + 24.247 + 4.466) - (31.342 + 0 + 0.611)
=5.163

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.856 + 31.595 + 5.403) - (22.824 + 0 + 0.532)
=16.498

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PuriBlood Medical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-45.49/1375.369
=-3.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PuriBlood Medical Co EBIT Related Terms

Thank you for viewing the detailed overview of PuriBlood Medical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PuriBlood Medical Co Business Description

Traded in Other Exchanges
N/A
Address
Gongye E. 9th Road, Baoshan Township, 2nd Floor, No.11, Hsinchu County, Baoshan, TWN
PuriBlood Medical Co Ltd is engaged in developing solutions for leukoreduction, cell separation, and anti-fouling materials. Its technology protects to supports living beings from medical devices to daily protection. The products of the company include Leukoreduction, Cell Separation, and P-tex.

PuriBlood Medical Co Headlines

No Headlines